Voyager Pharmaceutical Corporation Completes Second Phase II Clinical Study For Alzheimer's Disease
.
Alzheimer's Donation
Donate Online Now
.

Voyager Pharmaceutical Corporation announced Wednesday the completion of a Phase II study that assessed the safety and efficacy of leuprolide acetate in the treatment of mild-to-moderate Alzheimer's disease in men. The 48-week study, known as VP-AD-104, was a double-blind, placebo- controlled, multi-center study. It enrolled 119 men ages 65 and older with mild-to-moderate Alzheimer's disease. "The completion of this Phase II study in men is a major clinical achievement for Voyager," said Patrick Smith, president and CEO of the company. "Furthermore, nearly 90 percent of eligible subjects elected to enroll in the extension study." Voyager will complete data analyses during the next several weeks. Voyager completed VP-AD-103, a similar Phase II study in women, in 2005. Previously reported results from ALADDIN 103 showed stabilization of cognitive decline over 48 weeks in a subgroup of patients taking acetylcholinesterase inhibitors, the current standard of care, and leuprolide acetate. Voyager will be presenting additional Phase II trial data during the 10th International Conference on Alzheimer's Disease and Related Disorders, presented by the Alzheimer's Association. During the conference, Voyager will also report on the progress of its two active Phase III trials for Alzheimer's disease. The conference will be held in Madrid, Spain from July 15 - 20, 2006. For more information on Voyager's ongoing Phase III clinical trial or on the scientific premise upon which this treatment is founded, please go to http://www.voyagerpharma.com.

Alzheimer's vaccine candidate shows promiseSwissinfo - Switzerland... hallmark of the disease. Beta-amyloid proteins amass in the brain when a person suffers from Alzheimer's. These so-called plaques ...
Scientists Working On Alzheimer's VaccineWBAL Channel.com - Baltimore,MD,USA... The vaccine was administered through nose drops and targeted only the region of the amyloid-beta protein. Distributed by Internet Broadcasting Systems, Inc. ...
Research Reveals Alzheimer's Beginnings in Brain CellsNewswise (press release) - USAExperts have long known that a buildup of beta-amyloid protein "plaques" around and between neurons is a hallmark of Alzheimer's disease. ...